Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939802 | 0.89 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBTMPRSS2 | |
| SCHEMBL25821882 | 0.89 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBTMPRSS2 | |
| SCHEMBL30921698 | 0.89 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBTMPRSS2 | |
| SCHEMBL25825375 | 0.84 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL25826835 | 0.83 | TMPRSS2 (0.47) | TMPRSS2PIK3CDACVRL1 | |
| SCHEMBL12393281 | 0.83 | TMPRSS2 (0.44) | PI4KAPI4K2BPI4K2API4KBTMPRSS2 | |
| SCHEMBL22142989 | 0.83 | TMPRSS2 (0.44) | PI4KAPI4K2BPI4K2API4KBTMPRSS2 | |
| SCHEMBL30418526 | 0.83 | TMPRSS2 (0.44) | PI4KAPI4K2BPI4K2API4KBTMPRSS2 | |
| SCHEMBL26319768 | 0.83 | TMPRSS2 (0.44) | PI4KAPI4K2BPI4K2API4KBTMPRSS2 | |
| SCHEMBL26878544 | 0.83 | TMPRSS2 (0.44) | PI4KAPI4K2BPI4K2API4KBTMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | PI4KA 757/4885PI4K2B 633/4885PI4K2A 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.